High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions

被引：0
|
作者：
Jorge Maurino
Javier Sotoca
Ángel P. Sempere
Luis Brieva
Carlos López de Silanes
Ana B. Caminero
María Terzaghi
Julia Gracia-Gil
Gustavo Saposnik
机构：
[1] Roche Farma,Medical Department
[2] Hospital Universitari Mútua de Terrassa,Department of Neurology
[3] Hospital General Universitario de Alicante,Department of Neurology
[4] Hospital Universitari Arnau de Vilanova,Department of Neurology
[5] Hospital Universitario de Torrejón,Department of Neurology
[6] Complejo Asistencial de Ávila,Department of Neurology
[7] University of Toronto,Decision Neuroscience Unit, Li Ka Shing Institute
[8] Complejo Hospitalario Universitario de Albacete,Department of Neurology
[9] University of Toronto,Division of Neurology, Department of Medicine, St. Michael’s Hospital
[10] University of Zurich,Laboratory for Social and Neural System Research, Department of Economics
来源：
The Patient - Patient-Centered Outcomes Research | 2021年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：241 / 248
页数：7
相关论文
共 50 条
  • [31] Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
    Massimo Filippi
    Maria Pia Amato
    Diego Centonze
    Paolo Gallo
    Claudio Gasperini
    Matilde Inglese
    Francesco Patti
    Carlo Pozzilli
    Paolo Preziosa
    Maria Trojano
    Journal of Neurology, 2022, 269 : 6690 - 6691
  • [32] Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
    Massimo Filippi
    Romano Danesi
    Tobias Derfuss
    Martin Duddy
    Paolo Gallo
    Ralf Gold
    Eva Kubala Havrdová
    Barbara Kornek
    Francesco Saccà
    Mar Tintoré
    Jörg Weber
    Maria Trojano
    Journal of Neurology, 2022, 269 : 1670 - 1677
  • [33] Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Martinez-Lopez, Iciar
    Maurino, Jorge
    Sanmartin-Fenollera, Patricia
    Ontanon-Nasarre, Ana
    Santiago-Perez, Alejandro
    Moya-Carmona, Isabel
    Gustavo Garcia-Collado, Carlos
    Fernandez-Del Olmo, Raquel
    Garcia-Arcelay, Elena
    Sarmiento, Monica
    Carreno, Agata
    Perez-Encinas, Montserrat
    PHARMACY, 2020, 8 (02)
  • [34] Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis
    Hartung, Hans-Peter
    Meuth, Sven G.
    Thompson, Alan J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (10) : 1473 - 1476
  • [35] ESTIMATING THE FISCAL CONSEQUENCES OF INVESTMENTS IN DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mennini, F. S.
    Kotsopoulos, N.
    Connolly, M.
    Gianinazzi, M.
    Pellirone, M.
    Marcellusi, A.
    VALUE IN HEALTH, 2020, 23 : S627 - S628
  • [36] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [37] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [38] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [39] Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis
    Manzano, A.
    Eskyte, I
    Ford, H. L.
    Pavitt, S. H.
    Potrata, B.
    Schmierer, K.
    Chataway, J.
    Webb, E. J. D.
    Meads, D.
    Pepper, G.
    Bekker, H. L.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [40] Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Abdel-mannan, Omar A.
    Manchoon, Celeste
    Rossor, Thomas
    Southin, Justine-Clair
    Tur, Carmen
    Brownlee, Wallace
    Byrne, Susan
    Chitre, Manali
    Coles, Alasdair
    Forsyth, Rob
    Kneen, Rachel
    Mankad, Kshitij
    Ram, Dipak
    West, Siobhan
    Wright, Sukhvir
    Wassmer, Evangeline
    Lim, Ming
    Ciccarelli, Olga
    Hemingway, Cheryl
    Hacohen, Yael
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (04):
12345